News Neumora laid low by depression trial failure The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.
News Roche licenses Innovent ADC that could challenge Amgen drug Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.
News Flagship-backed AI startup Valo shelves eye disease drug Valo Health will no longer develop its ROCK1/2 inhibitor for diabetic retinopathy on its own after a trial readout but will seek to partner the drug.
News New data could widen use of Novartis' SMA therapy Zolgensma Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.
News Pfizer ducks out of Sangamo haemophilia A alliance Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.
News Amid BIOSECURE Act speculation, WuXi AppTec sells unit WuXi AppTec has agreed to sell a business unit serving the cell and gene therapy (CGT) sector to private equity firm Altaris for an undisclosed sum
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
